Jan Korabecny, Ladislav Janovec, Kamil Musilek, Filip Zemek, Anna Horova, Eugenie Nepovimova, Rafael Dolezal, Veronika Opletalova, Jana Hroudova, Zdenek Fisar, Young-Sik Jung and Kamil Kuca Pages 291 - 297 ( 7 )
Cholinesterase inhibitors play an essential role in the treatment of Alzheimer’s disease. Since their first introduction over a decade ago, they are an indispensable part of Alzheimer’s disease therapy and remain at the forefront of scientific interest worldwide. In this manuscript new analogs of THA and 7-MEOTA were designed, synthesized, and evaluated for their inhibitory activity against both acetylcholinesterase and butyrylcholinesterase. Cholinergic properties were investigated and quantified with respect to their side chain residues (aromatic or alicyclic). All synthesized compounds proved to have potent inhibitory activity at micromolar range. Moreover, compound 4 demonstrated promising efficacy and appears to be an ideal candidate for further testing.
7-methoxytacrine, acetylcholinesterase, Alzheimer`s disease, butyrylcholinesterase, inhibition selectivity, molecular modelling.
Centre of Advanced Studies, Faculty of Military Health Sciences, Trebesska 1575, 500 01 Hradec Kralove, Czech Republic.